Alto Neuroscience (ANRO) Net Income towards Common Stockholders (2023 - 2026)

Alto Neuroscience (ANRO) has 4 years of Net Income towards Common Stockholders data on file, last reported at -$26.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 64.82% year-over-year to -$26.1 million; the trailing twelve-month figure through Mar 2026 stood at -$2.3 billion (down 3461.52% YoY), and the FY2025 full-year result was -$111.9 million, down 15.18% from the prior year.
• Net Income towards Common Stockholders slipped to -$26.1 million in Q1 2026, from -$15.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$7.3 million in Q1 2023 to a low of -$1.9 billion in Q3 2025.
• A 4-year average of -$183.7 million and a median of -$15.8 million in 2025 frame the typical range for Net Income towards Common Stockholders.
• Peak annual rise in Net Income towards Common Stockholders reached 4.76% in 2025, while the deepest fall reached 10975.11% in 2025.
• Tracing ANRO's Net Income towards Common Stockholders over 4 years: stood at -$10.9 million in 2023, then sank by 39.08% to -$15.2 million in 2024, then dropped by 4.76% to -$15.9 million in 2025, then sank by 64.09% to -$26.1 million in 2026.
• Business Quant data shows ANRO's Net Income towards Common Stockholders at -$26.1 million in Q1 2026, -$15.9 million in Q4 2025, and -$1.9 billion in Q3 2025.